



Emma Walmsley

Chief Executive Officer

8 June 2021

Cautionary statement regarding forward-looking statements



This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

All expectations and targets regarding future performance and the dividend should be read together with the section "Outlook, assumptions and cautionary statements" on pages 42 and 43 of our first quarter 2021 earnings release.

Creating significant long-term shareholder value with two new companies



2017

Innovation

Performance

Trust

Culture

- ✓ Invest in R&D pipeline and improve productivity
- ✓ Sharpen commercial execution, refocus portfolio, drive cost discipline
- ✓ Address group structure and capital allocation
- ✓ Drive culture of ambition and accountability while maintaining leadership in ESG

2022

New GSK

Update June 23 2021

New Consumer Healthcare

CMD H1 2022

Focused ESG approach to support delivery of long-term sustainable performance



Pricing/Access

Environment

Global Health & Health security

Product governance

Inclusion & Diversity

Operating standards



ESG areas of focus: Pricing and access



Pricing/Access

Environment

Global Health & Health security

Product governance

Inclusion & Diversity


Operating standards



ESG areas of focus: Global health and Health security



Pricing/Access	Environment
Global Health & Health security	Product governance
Inclusion & Diversity	Operating standards



ESG areas of focus: Inclusion and Diversity



Pricing/Access	Environment
Global Health & Health security	Product governance
Inclusion & Diversity	Operating standards

Commitments to accelerate progress on I&D by 2025

Gender	Increase female leaders (VP and above) to 45% globally
Ethnicity	Increase ethnically-diverse leaders (VP and above) to at least 30% in the US and 18% in the UK

ESG areas of focus: Environment



Pricing/Access	Environment
Global Health/ health security	Product governance
Inclusion & Diversity	Operating standards

Ambitious environmental targets

Climate action Net zero impact on climate by 2030

Nature action Positive impact on nature by 2030

The LEAF Coalition
Lowering Emissions by Accelerating Forest finance



PRINCIPAL PARTNER
UN CLIMATE CHANGE CONFERENCE UK 2021
IN PARTNERSHIP WITH ITALY

ESG areas of focus: Product Governance and Operating standards



Pricing/Access

Environment

Global Health/ health security

Product governance

Inclusion & Diversity

Operating standards



Integrating ESG into operations to ensure delivery



Integrated across operations and incentivised

Benchmarked with visible public commitments

Part of capital allocation approach



ESG leader in key ratings and indices



Access to
Medicine Index

1st

Dow Jones
Sustainability Index

2nd

in the Pharma sector

MSCI

AA

Sustainalytics

21.3

ESG risk rating

CDP

**A in water,
B in Carbon,**

Leader for Supplier
Engagement

Science
Based Targets

Accredited for

1.5°C

aligned emissions targets
(scopes 1,2 and 3)

Vigeo Eiris

1st

in the Pharma sector


Antimicrobial
Resistance
benchmark

**Lead pharma
company**

ESG performance to deliver health impact and shareholder returns



- ✓ Sustainable performance and long-term growth
- ✓ Trust for all stakeholders
- ✓ Reduced risk to operations
- ✓ Positive social impact



New GSK to positively impact the health of >2.5 bn people over 10 years



Q&A